ENSG00000115524 |
SF3B1 |
myelodysplastic syndrome |
sequence_alteration |
23.42% (869/3710) |
6 entries |
ENSG00000115524 |
SF3B1 |
Uveal Melanoma |
missense_variant |
15.75% (89/565) |
7 entries |
ENSG00000115524 |
SF3B1 |
hemangioblastoma |
sequence_alteration |
28.57% (10/35) |
1 entry |
ENSG00000115524 |
SF3B1 |
chronic lymphocytic leukemia |
missense_variant |
12.59% (367/2916) |
21 entries |
ENSG00000115524 |
SF3B1 |
myelodysplastic syndrome |
missense_variant |
23.42% (869/3710) |
33 entries |
ENSG00000115524 |
SF3B1 |
neoplasm |
missense_variant |
29.36% (32/109) |
2 entries |
ENSG00000115524 |
SF3B1 |
mucosal melanoma |
missense_variant |
23.61% (17/72) |
2 entries |
ENSG00000115524 |
SF3B1 |
chronic lymphocytic leukemia |
frameshift_variant |
12.59% (367/2916) |
1 entry |
ENSG00000115524 |
SF3B1 |
myelodysplastic syndrome |
conservative_inframe_deletion |
23.42% (869/3710) |
3 entries |
ENSG00000115524 |
SF3B1 |
chronic lymphocytic leukemia |
conservative_inframe_deletion |
12.59% (367/2916) |
4 entries |
ENSG00000115524 |
SF3B1 |
Mixed Cell Uveal Melanoma |
missense_variant |
21.88% (7/32) |
3 entries |
ENSG00000115524 |
SF3B1 |
basal cell carcinoma |
missense_variant |
2.941% (2/68) |
1 entry |
ENSG00000115524 |
SF3B1 |
esophageal squamous cell carcinoma |
sequence_alteration |
1.314% (9/685) |
2 entries |
ENSG00000115524 |
SF3B1 |
chronic myelomonocytic leukemia |
sequence_alteration |
4.452% (37/831) |
3 entries |
ENSG00000115524 |
SF3B1 |
polycythemia vera |
missense_variant |
1.29% (2/155) |
1 entry |
ENSG00000115524 |
SF3B1 |
Epithelioid Cell Uveal Melanoma |
missense_variant |
13.64% (3/22) |
2 entries |
ENSG00000115524 |
SF3B1 |
chronic myelomonocytic leukemia |
missense_variant |
4.452% (37/831) |
8 entries |
ENSG00000115524 |
SF3B1 |
non-small cell lung carcinoma |
missense_variant |
2.74% (6/219) |
4 entries |
ENSG00000115524 |
SF3B1 |
salivary gland adenoid cystic carcinoma |
missense_variant |
3.279% (2/61) |
1 entry |
ENSG00000115524 |
SF3B1 |
Breast Carcinoma by Gene Expression Profile |
missense_variant |
1.352% (17/1257) |
3 entries |
ENSG00000115524 |
SF3B1 |
squamous cell lung carcinoma |
stop_gained |
1.609% (15/932) |
1 entry |
ENSG00000115524 |
SF3B1 |
anaplastic oligodendroglioma |
missense_variant |
2.247% (2/89) |
1 entry |
ENSG00000115524 |
SF3B1 |
breast phyllodes tumor |
missense_variant |
2.609% (3/115) |
3 entries |
ENSG00000115524 |
SF3B1 |
Cervical Small Cell Carcinoma |
missense_variant |
25.0% (2/8) |
1 entry |
ENSG00000115524 |
SF3B1 |
laryngeal squamous cell carcinoma |
missense_variant |
4.878% (2/41) |
2 entries |
ENSG00000115524 |
SF3B1 |
Pleural Epithelioid Mesothelioma |
missense_variant |
2.451% (5/204) |
2 entries |
ENSG00000115524 |
SF3B1 |
breast ductal adenocarcinoma |
missense_variant |
2.712% (47/1733) |
6 entries |
ENSG00000115524 |
SF3B1 |
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
3.709% (24/647) |
1 entry |
ENSG00000115524 |
SF3B1 |
glioma |
missense_variant |
0.5% (3/600) |
1 entry |
ENSG00000115524 |
SF3B1 |
esophageal squamous cell carcinoma |
missense_variant |
1.314% (9/685) |
5 entries |
ENSG00000115524 |
SF3B1 |
Dysplasia in Ulcerative Colitis |
missense_variant |
25.0% (2/8) |
1 entry |
ENSG00000115524 |
SF3B1 |
bile duct adenocarcinoma |
missense_variant |
0.8977% (5/557) |
1 entry |
ENSG00000115524 |
SF3B1 |
nasopharyngeal squamous cell carcinoma |
missense_variant |
0.974% (3/308) |
2 entries |
ENSG00000115524 |
SF3B1 |
acute myeloid leukemia |
missense_variant |
2.676% (134/5007) |
13 entries |
ENSG00000115524 |
SF3B1 |
colon adenocarcinoma |
missense_variant |
2.617% (34/1299) |
8 entries |
ENSG00000115524 |
SF3B1 |
lung adenocarcinoma |
missense_variant |
1.812% (46/2538) |
8 entries |
ENSG00000115524 |
SF3B1 |
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive |
missense_variant |
8.333% (2/24) |
2 entries |
ENSG00000115524 |
SF3B1 |
prostate carcinoma |
missense_variant |
1.171% (5/427) |
2 entries |
ENSG00000115524 |
SF3B1 |
skin melanoma |
stop_gained |
3.323% (41/1234) |
2 entries |
ENSG00000115524 |
SF3B1 |
myelodysplastic syndrome |
stop_gained |
23.42% (869/3710) |
1 entry |
ENSG00000115524 |
SF3B1 |
diffuse large B-cell lymphoma |
missense_variant |
0.6803% (3/441) |
3 entries |
ENSG00000115524 |
SF3B1 |
central nervous system primitive neuroectodermal neoplasm |
missense_variant |
0.8929% (4/448) |
1 entry |
ENSG00000115524 |
SF3B1 |
Invasive Breast Carcinoma |
missense_variant |
6.383% (3/47) |
1 entry |
ENSG00000115524 |
SF3B1 |
Ampulla of Vater Carcinoma |
missense_variant |
2.353% (2/85) |
1 entry |
ENSG00000115524 |
SF3B1 |
small cell lung carcinoma |
missense_variant |
1.587% (7/441) |
4 entries |
ENSG00000115524 |
SF3B1 |
pancreatic ductal adenocarcinoma |
missense_variant |
3.257% (58/1781) |
4 entries |
ENSG00000115524 |
SF3B1 |
T-cell acute lymphoblastic leukemia |
missense_variant |
0.4813% (4/831) |
2 entries |
ENSG00000115524 |
SF3B1 |
prostate adenocarcinoma |
missense_variant |
1.691% (41/2424) |
5 entries |
ENSG00000115524 |
SF3B1 |
bladder transitional cell carcinoma |
missense_variant |
4.139% (19/459) |
2 entries |
ENSG00000115524 |
SF3B1 |
ulcerative colitis |
missense_variant |
33.33% (3/9) |
1 entry |
ENSG00000115524 |
SF3B1 |
medullary thyroid gland carcinoma |
missense_variant |
4.286% (3/70) |
2 entries |
ENSG00000115524 |
SF3B1 |
gastric adenocarcinoma |
missense_variant |
1.281% (13/1015) |
4 entries |
ENSG00000115524 |
SF3B1 |
Breast Carcinoma by Gene Expression Profile |
sequence_alteration |
1.352% (17/1257) |
2 entries |
ENSG00000115524 |
SF3B1 |
papillary thyroid carcinoma |
missense_variant |
0.3945% (2/507) |
2 entries |
ENSG00000115524 |
SF3B1 |
Pleural Mesothelioma |
missense_variant |
2.206% (3/136) |
1 entry |
ENSG00000115524 |
SF3B1 |
lobular breast carcinoma |
missense_variant |
2.555% (7/274) |
2 entries |
ENSG00000115524 |
SF3B1 |
small intestinal adenocarcinoma |
missense_variant |
9.524% (2/21) |
1 entry |
ENSG00000115524 |
SF3B1 |
squamous cell lung carcinoma |
missense_variant |
1.609% (15/932) |
2 entries |
ENSG00000115524 |
SF3B1 |
breast carcinoma |
frameshift_variant |
1.222% (22/1801) |
2 entries |
ENSG00000115524 |
SF3B1 |
female breast carcinoma |
missense_variant |
1.205% (5/415) |
2 entries |
ENSG00000115524 |
SF3B1 |
urothelial carcinoma |
missense_variant |
3.488% (3/86) |
1 entry |
ENSG00000115524 |
SF3B1 |
colon adenocarcinoma |
sequence_alteration |
2.617% (34/1299) |
1 entry |
ENSG00000115524 |
SF3B1 |
esophageal adenocarcinoma |
missense_variant |
2.194% (12/547) |
2 entries |
ENSG00000115524 |
SF3B1 |
diffuse gastric adenocarcinoma |
sequence_alteration |
3.659% (3/82) |
1 entry |
ENSG00000115524 |
SF3B1 |
skin melanoma |
sequence_alteration |
3.323% (41/1234) |
1 entry |
ENSG00000115524 |
SF3B1 |
brain glioblastoma |
missense_variant |
0.6595% (8/1213) |
2 entries |
ENSG00000115524 |
SF3B1 |
Mast Cell Neoplasm |
missense_variant |
2.632% (2/76) |
1 entry |
ENSG00000115524 |
SF3B1 |
colorectal adenocarcinoma |
sequence_alteration |
2.508% (40/1595) |
3 entries |
ENSG00000115524 |
SF3B1 |
Uveal Melanoma |
conservative_inframe_deletion |
15.75% (89/565) |
1 entry |
ENSG00000115524 |
SF3B1 |
melanoma |
missense_variant |
3.448% (5/145) |
3 entries |
ENSG00000115524 |
SF3B1 |
breast carcinoma |
missense_variant |
1.222% (22/1801) |
3 entries |
ENSG00000115524 |
SF3B1 |
cecum adenocarcinoma |
missense_variant |
3.704% (10/270) |
2 entries |
ENSG00000115524 |
SF3B1 |
acute myeloid leukemia |
sequence_alteration |
2.676% (134/5007) |
1 entry |
ENSG00000115524 |
SF3B1 |
skin melanoma |
missense_variant |
3.323% (41/1234) |
7 entries |
ENSG00000115524 |
SF3B1 |
Myelodysplastic/Myeloproliferative Neoplasm |
missense_variant |
4.938% (4/81) |
3 entries |
ENSG00000115524 |
SF3B1 |
rectal adenocarcinoma |
sequence_alteration |
1.812% (10/552) |
2 entries |
ENSG00000115524 |
SF3B1 |
colorectal adenocarcinoma |
stop_gained |
2.508% (40/1595) |
1 entry |
ENSG00000115524 |
SF3B1 |
Endometrial Endometrioid Adenocarcinoma |
sequence_alteration |
3.709% (24/647) |
1 entry |
ENSG00000115524 |
SF3B1 |
Gallbladder Adenocarcinoma |
missense_variant |
2.632% (5/190) |
2 entries |
ENSG00000115524 |
SF3B1 |
rectal adenocarcinoma |
missense_variant |
1.812% (10/552) |
4 entries |
ENSG00000115524 |
SF3B1 |
bladder carcinoma |
missense_variant |
4.1% (23/561) |
1 entry |
ENSG00000115524 |
SF3B1 |
essential thrombocythemia |
missense_variant |
1.932% (4/207) |
3 entries |
ENSG00000115524 |
SF3B1 |
hepatocellular carcinoma |
missense_variant |
0.9766% (10/1024) |
2 entries |
ENSG00000115524 |
SF3B1 |
clear cell renal carcinoma |
missense_variant |
0.9472% (14/1478) |
3 entries |
ENSG00000115524 |
SF3B1 |
colorectal adenocarcinoma |
missense_variant |
2.508% (40/1595) |
2 entries |
ENSG00000115524 |
SF3B1 |
acute myeloid leukemia |
amino_acid_insertion |
2.676% (134/5007) |
2 entries |
ENSG00000115524 |
SF3B1 |
chronic myelogenous leukemia |
missense_variant |
0.9009% (1/111) |
1 entry |
ENSG00000115524 |
SF3B1 |
leiomyosarcoma |
missense_variant |
1.0% (1/100) |
1 entry |
ENSG00000115524 |
SF3B1 |
colon adenocarcinoma |
stop_gained |
2.617% (34/1299) |
1 entry |
ENSG00000115524 |
SF3B1 |
Meningeal Melanocytoma |
missense_variant |
2.632% (1/38) |
1 entry |
ENSG00000115524 |
SF3B1 |
synovial sarcoma |
missense_variant |
2.381% (1/42) |
1 entry |
ENSG00000115524 |
SF3B1 |
anaplastic oligoastrocytoma |
missense_variant |
2.439% (1/41) |
1 entry |
ENSG00000115524 |
SF3B1 |
Epithelioid Cell Uveal Melanoma |
conservative_inframe_deletion |
13.64% (3/22) |
1 entry |
ENSG00000115524 |
SF3B1 |
Testicular Embryonal Carcinoma |
missense_variant |
4.762% (1/21) |
1 entry |
ENSG00000115524 |
SF3B1 |
Primary Melanocytic Lesion of Meninges |
missense_variant |
12.5% (1/8) |
1 entry |
ENSG00000115524 |
SF3B1 |
Myelodysplastic/Myeloproliferative Neoplasm |
sequence_alteration |
4.938% (4/81) |
1 entry |
ENSG00000115524 |
SF3B1 |
brain glioblastoma |
sequence_alteration |
0.6595% (8/1213) |
1 entry |
ENSG00000115524 |
SF3B1 |
small cell lung carcinoma |
stop_gained |
1.587% (7/441) |
1 entry |
ENSG00000115524 |
SF3B1 |
bladder transitional cell carcinoma |
conservative_inframe_deletion |
4.139% (19/459) |
1 entry |
ENSG00000115524 |
SF3B1 |
Fibrolamellar Carcinoma |
missense_variant |
5.556% (1/18) |
1 entry |
ENSG00000115524 |
SF3B1 |
Hodgkins lymphoma |
missense_variant |
3.125% (1/32) |
1 entry |
ENSG00000115524 |
SF3B1 |
prostate carcinoma |
sequence_alteration |
1.171% (5/427) |
1 entry |
ENSG00000115524 |
SF3B1 |
Tonsillar Squamous Cell Carcinoma |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000115524 |
SF3B1 |
prostate carcinoma |
frameshift_variant |
1.171% (5/427) |
1 entry |
ENSG00000115524 |
SF3B1 |
Granulocytic Sarcoma |
missense_variant |
4.0% (1/25) |
1 entry |
ENSG00000115524 |
SF3B1 |
Duodenal Adenocarcinoma |
missense_variant |
5.882% (1/17) |
1 entry |
ENSG00000115524 |
SF3B1 |
lobular breast carcinoma |
frameshift_variant |
2.555% (7/274) |
1 entry |
ENSG00000115524 |
SF3B1 |
Chronic Eosinophilic Leukemia, Not Otherwise Specified |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000115524 |
SF3B1 |
clear cell renal carcinoma |
sequence_alteration |
0.9472% (14/1478) |
1 entry |
ENSG00000115524 |
SF3B1 |
cecum adenocarcinoma |
stop_gained |
3.704% (10/270) |
1 entry |
ENSG00000115524 |
SF3B1 |
follicular thyroid carcinoma |
missense_variant |
1.449% (1/69) |
1 entry |
ENSG00000115524 |
SF3B1 |
rectal adenocarcinoma |
frameshift_variant |
1.812% (10/552) |
1 entry |
ENSG00000115524 |
SF3B1 |
colon adenocarcinoma |
frameshift_variant |
2.617% (34/1299) |
1 entry |
ENSG00000115524 |
SF3B1 |
lung adenocarcinoma |
conservative_inframe_deletion |
1.812% (46/2538) |
1 entry |
ENSG00000115524 |
SF3B1 |
Gastrointestinal stromal tumor |
missense_variant |
0.5952% (1/168) |
1 entry |
ENSG00000115524 |
SF3B1 |
Colorectal Neuroendocrine Tumor G1 |
missense_variant |
20.0% (1/5) |
1 entry |
ENSG00000115524 |
SF3B1 |
head and neck squamous cell carcinoma |
missense_variant |
0.159% (1/629) |
1 entry |
ENSG00000115524 |
SF3B1 |
lung adenocarcinoma |
stop_gained |
1.812% (46/2538) |
1 entry |
ENSG00000115524 |
SF3B1 |
adenoid cystic carcinoma |
missense_variant |
33.33% (1/3) |
1 entry |
ENSG00000115524 |
SF3B1 |
HER2 Positive Breast Carcinoma |
missense_variant |
2.174% (3/138) |
1 entry |
ENSG00000115524 |
SF3B1 |
pharyngeal squamous cell carcinoma |
missense_variant |
0.6993% (1/143) |
1 entry |
ENSG00000115524 |
SF3B1 |
bile duct adenocarcinoma |
sequence_alteration |
0.8977% (5/557) |
1 entry |
ENSG00000115524 |
SF3B1 |
adenosquamous lung carcinoma |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000115524 |
SF3B1 |
benign blood vessel neoplasm |
missense_variant |
25.0% (1/4) |
1 entry |
ENSG00000115524 |
SF3B1 |
Salivary Gland Small Cell Carcinoma |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000115524 |
SF3B1 |
large cell lung carcinoma |
missense_variant |
5.263% (1/19) |
1 entry |
ENSG00000115524 |
SF3B1 |
Adrenal Gland Neuroblastoma |
sequence_alteration |
3.333% (2/60) |
1 entry |
ENSG00000115524 |
SF3B1 |
Ocular Sebaceous Carcinoma |
missense_variant |
4.348% (1/23) |
1 entry |
ENSG00000115524 |
SF3B1 |
gastric adenocarcinoma |
sequence_alteration |
1.281% (13/1015) |
1 entry |
ENSG00000115524 |
SF3B1 |
mesonephric adenocarcinoma |
missense_variant |
25.0% (1/4) |
1 entry |
ENSG00000115524 |
SF3B1 |
Chronic Neutrophilic Leukemia |
missense_variant |
25.0% (1/4) |
1 entry |
ENSG00000115524 |
SF3B1 |
Breast Carcinoma by Gene Expression Profile |
frameshift_variant |
1.352% (17/1257) |
1 entry |
ENSG00000115524 |
SF3B1 |
medulloblastoma |
missense_variant |
4.167% (1/24) |
1 entry |
ENSG00000115524 |
SF3B1 |
Uterine Carcinosarcoma |
missense_variant |
0.6757% (1/148) |
1 entry |
ENSG00000115524 |
SF3B1 |
cecum adenocarcinoma |
sequence_alteration |
3.704% (10/270) |
1 entry |
ENSG00000115524 |
SF3B1 |
non-small cell lung carcinoma |
sequence_alteration |
2.74% (6/219) |
1 entry |
ENSG00000115524 |
SF3B1 |
endometrial stromal sarcoma |
missense_variant |
6.25% (1/16) |
1 entry |
ENSG00000115524 |
SF3B1 |
Adrenal Gland Neuroblastoma |
missense_variant |
3.333% (2/60) |
1 entry |
ENSG00000115524 |
SF3B1 |
cervical adenocarcinoma |
missense_variant |
25.0% (1/4) |
1 entry |
ENSG00000115524 |
SF3B1 |
small cell lung carcinoma |
sequence_alteration |
1.587% (7/441) |
1 entry |
ENSG00000115524 |
SF3B1 |
bronchoalveolar adenocarcinoma |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000115524 |
SF3B1 |
T-cell acute lymphoblastic leukemia |
frameshift_variant |
0.4813% (4/831) |
1 entry |
ENSG00000115524 |
SF3B1 |
acute myeloid leukemia |
transcript_ablation |
2.676% (134/5007) |
1 entry |
ENSG00000115524 |
SF3B1 |
monoclonal B-cell lymphocytosis |
missense_variant |
1.562% (1/64) |
1 entry |
ENSG00000115524 |
SF3B1 |
Merkel cell skin cancer |
missense_variant |
1.064% (1/94) |
1 entry |
ENSG00000115524 |
SF3B1 |
esophageal squamous cell carcinoma |
stop_gained |
1.314% (9/685) |
1 entry |
ENSG00000115524 |
SF3B1 |
Parotid Gland Adenoid Cystic Carcinoma |
missense_variant |
7.143% (1/14) |
2 entries |
ENSG00000115524 |
SF3B1 |
ovarian clear cell adenocarcinoma |
missense_variant |
2.041% (1/49) |
1 entry |
ENSG00000115524 |
SF3B1 |
osteosarcoma |
sequence_alteration |
0.6579% (1/152) |
1 entry |